Official EU label nameGlossary entry 28752
THIOCTIC ACID
This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.
Global evidence snapshot
The resolved identity has matching regulatory evidence in 1 of 13 indexed market datasets: 1 country records and 0 EU Annex records. Every result and evidence gap is listed below.
Markets checked
13
Markets with evidence
1
Evidence gaps
12
Resolved identifiers
2
A missing local match is not permission, approval or proof of safety. It means no strong identity match was resolved in that indexed dataset.
Resolved substance identity
CAS:1077-28-7
EC:214-071-2
Ingredient index records:
3 matched or reported names
THIOCTIC ACIDThioctic acid [JAN]Thioctic acid
Regulatory evidence in all 13 markets
Open each matched record for its scope, concentration, conditions, warnings and official source version.
Swipe or scroll horizontally to see dataset coverage and next actions.
| Market | Result | Records | Dataset | Meaning / next action |
|---|---|---|---|---|
| European Union EU | No local match | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | No local match | 0 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework. |
| Canada CA | No local match | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | No local match | 0 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative. |
| ASEAN ASEAN | No local match | 0 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Regional annex coverage does not replace member-state implementation dates, notifications or national deviations. |
| China CN | No local match | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | Restricted | 1Open record 1 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | Review every linked record and exact conditions. |
| South Korea KR | No local match | 0 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Korean source wording is canonical and other positive lists/notices may still apply to the formulation. |
| United States US | No local match | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | No local match | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | No local match | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | No local match | 0 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | The standards are separate controlled publications; absence from a locally indexed excerpt is not permission. |
| Saudi Arabia SA | No local match | 0 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply. |
No market rows match this filter.
Matching market records and conditions
Chemical identity and properties
CAS 1077-28-7PubChem CID 864
alpha Lipoic acid
- IUPAC name
- 5-(dithiolan-3-yl)pentanoic acid
- Molecular formula
- C8H14O2S2
- Molecular weight
- 206.3 g/mol
- Exact mass
- 206.04352203 Da
- XLogP3
- 1.7
- Topological polar surface area
- 87.9 Ų
- Hydrogen-bond donors
- 1
- Hydrogen-bond acceptors
- 4
- Covalent units
- 1
- Defined stereocentres
- 0
Also known as
thioctic acidalpha-Lipoic acid6,8-Thioctic acidBiletanDL-6,8-Thioctic acidThioctsanthioctateThiocacid
16 more reported names
ThioctanTioctic AcidAcidum thiocticumA-lipoicum acidumLipoic acid, dl-Lipoic acid, alphabiomoliponAlphaLipogammabiomo liponespa liponAlpha LipogammaPleomix AlphaVerla LiponAlphaLipon StadaAlpha Lippon ALAlpha Lipon Stada
External database identifiers
- ChEBI:CHEBI:16494
- ChEMBL:CHEMBL33864
- EPA DTXSID:DTXSID7025508
- PubMed:22654724
- PubMed:22448096
- PubMed:22384101
- PubMed:22374556
- PubMed:22363901
- PubMed:22272085
- PubMed:22242957
- PubMed:22163871
- PubMed:22163517
- PubMed:22146387
- PubMed:22125679
- PubMed:22125537
Evidence from additional scientific databases
NIH PubChem PUG-View
Exact identifier match864
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: Forms yellowish flakes Source: Hazardous Substances Data Bank (HSDB)
- Dissociation Constants: pKa = 5.10 Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: 47.5-48 °C Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Yellow powder; solubility in ethanol: 50 mg/mL /Synthetic, oxidized form/ Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Soluble in methanol, ethanol, diethyl ether and chloroform Source: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Note: This chemical does not meet GHS hazard criteria for 6.5% (28 of 430) of reports. Source: European Chemicals Agency (ECHA)
- Signal: Warning Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (93.5%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (48.6%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (46.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (47%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H411 (46.5%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 430 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 28 of 430 reports by companies.; There are 14 notifications provided by 402 of 430 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Note: This chemical does not meet GHS hazard criteria for 42.3% (52 of 123) of reports. Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (57.7%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (31.7%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (31.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335 (31.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]; H412 (19.5%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 123 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 52 of 123 reports by companies.; There are 7 notifications provided by 71 of 123 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Health Effects: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, incre Source: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: ALA is generally considered a safe drug. A daily dose of 200 mg/day to 2400 mg/day of ALA is deemed safe without significant adverse effects. However, there is no reported safe dose in children.; A notable case in literature demonstrated status epilepticus (SE) that subsided within a few days. The seizures were treated per normal standards for SE.; In the last 2 decades, there have been few reported cases of ALA toxicity in humans. Most of these cases occur in children and are treatable. Though there is no established lethal dosage of ALA for humans, studies have shown that a high dose of 121 mg/kg body weight/day was associated with alterations in liver enzymes and liver function. Therefore, there are potentially harmful adverse effects from overdosing on ALA, and more studies are necessary to determine the toxicity. Source: StatPearls
- Toxicity Summary: (R)-lipoic acid is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as Source: Toxin and Toxin Target Database (T3DB)
- Uses: Nutrition, biochemical research /Thioctic acid, dl-form/ Source: Hazardous Substances Data Bank (HSDB)
- Uses: THERAPEUTIC CATEGORY: Treatment of liver disease; antidote to poisonous mushrooms (Amanita species). Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >7500; Consumption (g per capita; approx.) in Germany (2009): 0.0916; Calculated removal (%): 96.4 Source: NORMAN Suspect List Exchange
- Uses: For nutritional supplementation, also for treating dietary shortage or imbalance. Source: Toxin and Toxin Target Database (T3DB)
Mapped by: Existing checksum-valid CAS to unique PubChem CID match. Retrieved: 2026-08-31. Open source record
Scientific classifications and hazard annotations provide context and do not replace the market-specific regulatory decision shown above.
Additional source coverage and match status
| Source | Result | Checked |
|---|---|---|
| NIH PubChem PUG-View | Exact match | 2026-08-31 |
A recorded no-match is useful evidence that the source was checked; it is not a claim that the substance does not exist elsewhere.
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Additional authoritative substance research
These source-specific lookups can add hazard, toxicology, identity and assessment context. A link is a research route, not a claim that the source contains an exact record.
Cosmetic Ingredient Review safety assessments
Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents
Independent expert review considered by FDA; not a government approval or binding market rule
Research this identityFDA Global Substance Registration System
UNII identifiers, preferred names, substance types, codes and public substance relationships
Identity registry only; UNII availability does not imply FDA review or approval
Research this identityILO/WHO International Chemical Safety Cards
Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals
International occupational chemical-safety reference; not cosmetic-use approval
Research this identityJapan NITE-CHRIP
Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information
Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules
Research this identityNIOSH Pocket Guide to Chemical Hazards
REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals
US occupational-health guidance and limits; not a cosmetic ingredient decision
Research this identityOECD eChemPortal
Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records
Discovery gateway; each linked authority remains responsible for its data
Research this identityUS EPA CompTox CTX APIs
DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data
Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality
Research this identityContinue the compliance check
1. Confirm identity
Match the supplier specification, CAS/EC identifiers and composition to this official label name. Similar wording is not proof of chemical equivalence.
2. Review restrictions
Check every exact Annex record shown above, plus CMR, nanomaterial, SCCS and later-amendment requirements that may apply.
3. Verify the formula
Evaluate concentration, product type, purity, warnings, claims and each target market before making a compliance decision.
Official source and scope
Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.
Open official Decision